CD5L as a promising biological therapeutic for treating sepsis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 17 02 2023
accepted: 29 04 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 15 5 2024
Statut: epublish

Résumé

Sepsis results from systemic, dysregulated inflammatory responses to infection, culminating in multiple organ failure. Here, we demonstrate the utility of CD5L for treating experimental sepsis caused by cecal ligation and puncture (CLP). We show that CD5L's important features include its ability to enhance neutrophil recruitment and activation by increasing circulating levels of CXCL1, and to promote neutrophil phagocytosis. CD5L-deficient mice exhibit impaired neutrophil recruitment and compromised bacterial control, rendering them susceptible to attenuated CLP. CD5L

Identifiants

pubmed: 38750020
doi: 10.1038/s41467-024-48360-8
pii: 10.1038/s41467-024-48360-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4119

Informations de copyright

© 2024. The Author(s).

Références

Lai, X., Wang, J., Duan, J., Gong, Y. & Cao, J. Apoptosis inhibitor of macrophage differentiates bacteria from influenza or COVID-19 in hospitalized adults with community-acquired pneumonia. J. Infect. 84, 579–613 (2022).
pubmed: 34954255 doi: 10.1016/j.jinf.2021.12.027
Chen, T., Duan, J., Li, M., Wu, X. & Cao, J. Assessment of serum CD5L as a biomarker to distinguish etiology and predict mortality in adults with pneumonia. J. Infect. 80, 469–496 (2020).
pubmed: 31891727 doi: 10.1016/j.jinf.2019.12.003
Lai, X., Xiang, Y., Zou, L., Li, Y. & Zhang, L. Elevation of serum CD5L concentration is correlated with disease activity in patients with systemic lupus erythematosus. Int. Immunopharmacol. 63, 311–316 (2018).
pubmed: 30173083 doi: 10.1016/j.intimp.2018.07.022
Tarazon, E. et al. Plasma CD5L and non-invasive diagnosis of acute heart rejection. J. Heart Lung Transplant. 39, 257–266 (2020).
pubmed: 31883820 doi: 10.1016/j.healun.2019.11.004
Castelblanco, E. et al. Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease. Aging 13, 22690–22709 (2021).
pubmed: 34629330 pmcid: 8544330 doi: 10.18632/aging.203615
Cheng, Q., Lai, X., Yang, L., Yang, H. & Luo, Y. Serum CD5L predicts acute lung parenchymal injury and acute respiratory distress syndrome in trauma patients. Medicine (Baltimore) 100, e27219 (2021).
pubmed: 34596119 doi: 10.1097/MD.0000000000027219
Okanoue, T. et al. Serum levels of immunoglobulin M-free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatol. Res. 52, 998–1008 (2022).
Choi, E. S. et al. CD5L as an extracellular vesicle-derived biomarker for liquid biopsy of lung cancer. Diagnostics 11, 620 (2021).
pubmed: 33808296 pmcid: 8067192 doi: 10.3390/diagnostics11040620
Nock, S. et al. CD5L constitutes a novel biomarker for integrated hepatic thyroid hormone action. Thyroid 30, 908–923 (2020).
pubmed: 32183611 doi: 10.1089/thy.2019.0635
Yamazaki, T. et al. Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. PLoS One 9, e109123 (2014).
pubmed: 25302503 pmcid: 4193837 doi: 10.1371/journal.pone.0109123
Oskam, N. et al. CD5L is a canonical component of circulatory IgM. Proc. Natl Acad. Sci. USA 120, e2311265120 (2023).
pubmed: 38055740 doi: 10.1073/pnas.2311265120
Sarrias, M. R. et al. Biochemical characterization of recombinant and circulating human Spalpha. Tissue Antigens 63, 335–344 (2004).
pubmed: 15009805 doi: 10.1111/j.0001-2815.2004.00193.x
Tissot, J. D. et al. IgM are associated to Sp alpha (CD5 antigen-like). Electrophoresis 23, 1203–1206 (2002).
pubmed: 11981870 doi: 10.1002/1522-2683(200204)23:7/8<1203::AID-ELPS1203>3.0.CO;2-1
Miyazaki, T., Yamazaki, T., Sugisawa, R., Gershwin, M. E. & Arai, S. AIM associated with the IgM pentamer: attackers on stand-by at aircraft carrier. Cell Mol. Immunol. 15, 563–574 (2018).
pubmed: 29375122 pmcid: 6078943 doi: 10.1038/cmi.2017.141
Arai, S. et al. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep. 3, 1187–1198 (2013).
pubmed: 23562157 doi: 10.1016/j.celrep.2013.03.006
Hiramoto, E. et al. The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein. Sci. Adv. 4, eaau1199 (2018).
pubmed: 30324136 pmcid: 6179379 doi: 10.1126/sciadv.aau1199
Miyazaki, T., Hirokami, Y., Matsuhashi, N., Takatsuka, H. & Naito, M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J. Exp. Med. 189, 413–422 (1999).
pubmed: 9892623 pmcid: 2192994 doi: 10.1084/jem.189.2.413
Joseph, S.B. et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119, 299–309 (2004).
Arai, S. et al. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 1, 201–213 (2005).
pubmed: 16054063 doi: 10.1016/j.cmet.2005.02.002
Cardoso, M. S. et al. Physical interactions with bacteria and protozoan parasites establish the scavenger receptor SSC4D as a broad-spectrum pattern recognition receptor. Front. Immunol. 12, 760770 (2021).
pubmed: 35003072 pmcid: 8739261 doi: 10.3389/fimmu.2021.760770
Bessa Pereira, C. et al. The scavenger receptor SSc5D physically interacts with bacteria through the SRCR-containing N-terminal domain. Front. Immunol. 7, 9 (2016).
doi: 10.3389/fimmu.2016.00416
Bikker, F. J. et al. Identification of the bacteria-binding peptide domain on salivary agglutinin (gp-340/DMBT1), a member of the scavenger receptor cysteine-rich superfamily. J. Biol. Chem. 277, 32109–32115 (2002).
pubmed: 12050164 doi: 10.1074/jbc.M203788200
Sarrias, M. R. et al. A role for human Sp alpha as a pattern recognition receptor. J. Biol. Chem. 280, 35391–35398 (2005).
pubmed: 16030018 doi: 10.1074/jbc.M505042200
Martínez, V. G. et al. The macrophage soluble receptor AIM/Api6/CD5L displays a broad pathogen recognition spectrum and is involved in early response to microbial aggression. Cell. Mol. Immunol. 11, 343–354 (2014).
pubmed: 24583716 pmcid: 4085514 doi: 10.1038/cmi.2014.12
Kuwata, K. et al. AIM inhibits apoptosis of T cells and NKT cells in Corynebacterium-induced granuloma formation in mice. Am. J. Pathol. 162, 837–847 (2003).
pubmed: 12598318 pmcid: 1868086 doi: 10.1016/S0002-9440(10)63880-1
Gao, X., Yan, X., Zhang, Q., Yin, Y. & Cao, J. CD5L contributes to the pathogenesis of methicillin-resistant Staphylococcus aureus-induced pneumonia. Int. Immunopharmacol. 72, 40–47 (2019).
pubmed: 30959370 doi: 10.1016/j.intimp.2019.03.057
Sanjurjo, L. et al. CD5L promotes M2 macrophage polarization through autophagy-mediated upregulation of ID3. Front. Immunol. 9, 480 (2018).
pubmed: 29593730 pmcid: 5858086 doi: 10.3389/fimmu.2018.00480
Wang, C. et al. CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity. Cell 163, 1413–1427 (2015).
pubmed: 26607793 pmcid: 4671820 doi: 10.1016/j.cell.2015.10.068
Weng, D. et al. CD5L attenuates allergic airway inflammation by expanding CD11c(high) alveolar macrophages and inhibiting NLRP3 inflammasome activation via HDAC2. Immunology 167, 384–397 (2022).
Arai, S. et al. Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat. Med. 22, 183–193 (2016).
pubmed: 26726878 doi: 10.1038/nm.4012
Maehara, N. et al. AIM/CD5L attenuates DAMPs in the injured brain and thereby ameliorates ischemic stroke. Cell Rep. 36, 109693 (2021).
pubmed: 34525359 doi: 10.1016/j.celrep.2021.109693
Kurokawa, J. et al. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. Cell Metab. 11, 479–492 (2010).
pubmed: 20519120 doi: 10.1016/j.cmet.2010.04.013
Tomita, T. et al. Apoptosis inhibitor of macrophage ameliorates fungus-induced peritoneal injury model in mice. Sci Rep. 7, 6450 (2017).
pubmed: 28743989 pmcid: 5527077 doi: 10.1038/s41598-017-06824-6
Matsuura, K. et al. Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1. Commun. Biol. 5, 783 (2022).
pubmed: 35922481 pmcid: 9349198 doi: 10.1038/s42003-022-03750-w
Kimura, H. et al. Orchestrating role of apoptosis inhibitor of macrophage in the resolution of acute lung injury. J. Immunol. 199, 3870–3882 (2017).
pubmed: 29070674 doi: 10.4049/jimmunol.1601798
Singer, M. et al. The third International Consensus definitions for sepsis and septic Shock (Sepsis-3). JAMA 315, 801–810 (2016).
pubmed: 26903338 pmcid: 4968574 doi: 10.1001/jama.2016.0287
Rudd, K. E. et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 395, 200–211 (2020).
pubmed: 31954465 pmcid: 6970225 doi: 10.1016/S0140-6736(19)32989-7
Gao, X. et al. Assessment of apoptosis inhibitor of macrophage/CD5L as a biomarker to predict mortality in the critically ill with sepsis. Chest 156, 696–705 (2019).
pubmed: 31154043 doi: 10.1016/j.chest.2019.04.134
Libert, C. et al. Part II: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for types of infections and organ dysfunction endpoints. Shock 51, 23–32 (2019).
pubmed: 30106873 pmcid: 6296883 doi: 10.1097/SHK.0000000000001242
Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal ligation and puncture: The gold standard model for polymicrobial sepsis? Trends Microbiol 19, 198–208 (2011).
pubmed: 21296575 doi: 10.1016/j.tim.2011.01.001
McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I interferons in infectious disease. Nat Rev Immunol 15, 87–103 (2015).
pubmed: 25614319 pmcid: 7162685 doi: 10.1038/nri3787
Boxx, G. M. & Cheng, G. The roles of Type I Interferon in bacterial infection. Cell Host Microbe 19, 760–769 (2016).
pubmed: 27281568 pmcid: 5847370 doi: 10.1016/j.chom.2016.05.016
Zhang, Y. Y. & Ning, B. T. Signaling pathways and intervention therapies in sepsis. Signal Transduct Target Ther. 6, 407 (2021).
pubmed: 34824200 pmcid: 8613465 doi: 10.1038/s41392-021-00816-9
Tanaka, T., Narazaki, M. & Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect Biol. 6, a016295 (2014).
pubmed: 25190079 pmcid: 4176007 doi: 10.1101/cshperspect.a016295
Zanders, L. et al. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting. J. Cachexia Sarcopenia Muscle 13, 713–727 (2022).
pubmed: 34821076 doi: 10.1002/jcsm.12867
Bar-Or, D. et al. Sepsis, oxidative stress, and hypoxia: Are there clues to better treatment? Redox Rep. 20, 193–197 (2015).
pubmed: 25803628 pmcid: 6837729 doi: 10.1179/1351000215Y.0000000005
Majmundar, A. J., Wong, W. J. & Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294–309 (2010).
pubmed: 20965423 pmcid: 3143508 doi: 10.1016/j.molcel.2010.09.022
Hotchkiss, R. S. et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 166, 6952–6963 (2001).
pubmed: 11359857 doi: 10.4049/jimmunol.166.11.6952
Gong, Y. et al. Oncostatin M is a prognostic biomarker and inflammatory mediator for sepsis. J. Infect. Dis 221, 1989–1998 (2020).
pubmed: 31930328 doi: 10.1093/infdis/jiaa009
Novick, D. et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14, 334–342 (2001).
pubmed: 11497494 doi: 10.1006/cyto.2001.0914
Duprez, L. et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 35, 908–918 (2011).
pubmed: 22195746 doi: 10.1016/j.immuni.2011.09.020
Wang, Q. et al. Identification of biomarkers related to sepsis diagnosis based on bioinformatics and machine learning and experimental verification. Front. Immunol. 14, 1087691 (2023).
pubmed: 37449204 pmcid: 10337583 doi: 10.3389/fimmu.2023.1087691
Andrade, E. B. et al. TLR2-induced IL-10 production impairs neutrophil recruitment to infected tissues during neonatal bacterial sepsis. J. Immunol. 191, 4759–4768 (2013).
pubmed: 24078699 doi: 10.4049/jimmunol.1301752
Herzig, D. et al. STAT1-deficient mice are resistant to cecal ligation and puncture-induced septic shock. Shock 38, 395–402 (2012).
pubmed: 22777121 pmcid: 3445722 doi: 10.1097/SHK.0b013e318265a2ab
Wang, A., Kang, X., Wang, J. & Zhang, S. IFIH1/IRF1/STAT1 promotes sepsis associated inflammatory lung injury via activating macrophage M1 polarization. Int. Immunopharmacol. 114, 109478 (2023).
pubmed: 36462334 doi: 10.1016/j.intimp.2022.109478
AbdAllah, N. B. et al. MYD88, NFKB1, and IL6 transcripts overexpression are associated with poor outcomes and short survival in neonatal sepsis. Sci. Rep. 11, 13374 (2021).
pubmed: 34183713 pmcid: 8238937 doi: 10.1038/s41598-021-92912-7
Yan, X. et al. Time Series Transcriptomic Analysis by RNA Sequencing Reveals a Key Role of PI3K in Sepsis-Induced Myocardial Injury in Mice. Front. Physiol. 13, 903164 (2022).
pubmed: 35721566 pmcid: 9198581 doi: 10.3389/fphys.2022.903164
Brealey, D. et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360, 219–223 (2002).
pubmed: 12133657 doi: 10.1016/S0140-6736(02)09459-X
Omachi, A., Sharma, A. C., Alden, K. J., Sam, A. D. & Ferguson, J. L. Induction of peritoneal sepsis increases the susceptibility of isolated hearts to a calcium paradox-mediated injury. Shock 17, 193–198 (2002).
pubmed: 11900337 doi: 10.1097/00024382-200203000-00006
Brealey, D. et al. Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R491–R497 (2004).
pubmed: 14604843 doi: 10.1152/ajpregu.00432.2003
Patil, N. K., Parajuli, N., MacMillan-Crow, L. A. & Mayeux, P. R. Inactivation of renal mitochondrial respiratory complexes and manganese superoxide dismutase during sepsis: mitochondria-targeted antioxidant mitigates injury. Am. J. Physiol. Renal Physiol. 306, F734–F743 (2014).
pubmed: 24500690 pmcid: 3962604 doi: 10.1152/ajprenal.00643.2013
Zingarelli, B. et al. Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for study design and humane modeling endpoints. Shock 51, 10–22 (2019).
pubmed: 30106874 pmcid: 6296871 doi: 10.1097/SHK.0000000000001243
Sanchez-Moral, L. et al. Multifaceted Roles of CD5L in Infectious and Sterile Inflammation. Int. J. Mol. Sci. 22, 4076 (2021).
Gao, X. et al. Therapeutic targeting of apoptosis inhibitor of macrophage/CD5L in sepsis. Am. J. Respir. Cell Mol. Biol. 60, 323–334 (2019).
pubmed: 30326743 doi: 10.1165/rcmb.2018-0272OC
Ghosn, E. E. et al. Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc. Natl Acad. Sci. USA 107, 2568–2573 (2010).
pubmed: 20133793 pmcid: 2823920 doi: 10.1073/pnas.0915000107
Goswami, D. G. et al. Large peritoneal macrophages and transitional premonocytes promote survival during abdominal sepsis. Immunohorizons 5, 994–1007 (2021).
pubmed: 34965966 doi: 10.4049/immunohorizons.2100086
Simons, E. R. Measurement of phagocytosis and of the phagosomal environment in polymorphonuclear phagocytes by flow cytometry. Curr. Protoc. Cytom. 51, 9.31.1–9.31.10 (2010).
Schneider, M. Collecting resident or thioglycollate-elicited peritoneal macrophages. Methods Mol. Biol. 1031, 37–40 (2013).
pubmed: 23824884 doi: 10.1007/978-1-62703-481-4_4
Venereau, E., Ceriotti, C. & Bianchi, M. E. DAMPs from cell death to new life. Front. Immunol. 6, 422 (2015).
pubmed: 26347745 pmcid: 4539554 doi: 10.3389/fimmu.2015.00422
Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248–251 (1999).
pubmed: 10398600 doi: 10.1126/science.285.5425.248
Moser, B., Clark-Lewis, I., Zwahlen, R. & Baggiolini, M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J. Exp. Med. 171, 1797–1802 (1990).
pubmed: 2185333 doi: 10.1084/jem.171.5.1797
Martínez, V. G., Moestrup, S. K., Holmskov, U., Mollenhauer, J. & Lozano, F. The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis. Pharmacol. Rev. 63, 967–1000 (2011).
pubmed: 21880988 doi: 10.1124/pr.111.004523
Jarczak, D., Kluge, S. & Nierhaus, A. Sepsis-pathophysiology and therapeutic concepts. Front. Med. 8, 628302 (2021).
doi: 10.3389/fmed.2021.628302
Otto, G. P. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 15, R183 (2011).
pubmed: 21798063 pmcid: 3387626 doi: 10.1186/cc10332
De Filippo, K., Henderson, R. B., Laschinger, M. & Hogg, N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J. Immunol. 180, 4308–4315 (2008).
pubmed: 18322244 doi: 10.4049/jimmunol.180.6.4308
De Filippo, K. et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 121, 4930–4937 (2013).
pubmed: 23645836 doi: 10.1182/blood-2013-02-486217
Gasperini, S., Calzetti, F., Russo, M. P., De Gironcoli, M. & Cassatella, M. A. Regulation of GRO alpha production in human granulocytes. J. Inflamm. 45, 143–151 (1995).
pubmed: 8597869
Pociask, D. A. et al. gammadelta T cells attenuate bleomycin-induced fibrosis through the production of CXCL10. Am. J. Pathol. 178, 1167–1176 (2011).
pubmed: 21356368 pmcid: 3070585 doi: 10.1016/j.ajpath.2010.11.055
Jackson-Jones, L. H. et al. Stromal cells covering omental fat-associated lymphoid clusters trigger formation of neutrophil aggregates to capture peritoneal contaminants. Immunity 52, 700–715. e706 (2020).
pubmed: 32294409 pmcid: 7156918 doi: 10.1016/j.immuni.2020.03.011
Paudel, S. et al. CXCL1 regulates neutrophil homeostasis in pneumonia-derived sepsis caused by Streptococcus pneumoniae serotype 3. Blood 133, 1335–1345 (2019).
pubmed: 30723078 pmcid: 6428667 doi: 10.1182/blood-2018-10-878082
Craciun, F. L., Schuller, E. R. & Remick, D. G. Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival. J. Immunol. 185, 6930–6938 (2010).
pubmed: 21041722 doi: 10.4049/jimmunol.1002300
Daix, T. et al. Multicentric standardized flow cytometry routine assessment of patients with sepsis to predict clinical worsening. Chest 154, 617–627 (2018).
pubmed: 29705219 doi: 10.1016/j.chest.2018.03.058
Camicia, G., Pozner, R. & de Larranaga, G. Neutrophil extracellular traps in sepsis. Shock 42, 286–294 (2014).
pubmed: 25004062 doi: 10.1097/SHK.0000000000000221
Shen, X., Cao, K., Zhao, Y. & Du, J. Targeting neutrophils in sepsis: from mechanism to translation. Front. Pharmacol. 12, 644270 (2021).
pubmed: 33912055 pmcid: 8072352 doi: 10.3389/fphar.2021.644270
Shukla, P. et al. Therapeutic interventions in sepsis: Current and anticipated pharmacological agents. Br. J. Pharmacol. 171, 5011–5031 (2014).
pubmed: 24977655 pmcid: 4253453 doi: 10.1111/bph.12829
Casaca, A., Nóvoa, A. & Mallo, M. Hoxb6 can interfere with somitogenesis in the posterior embryo through a mechanism independent of its rib-promoting activity. Development 143, 437–448 (2016).
pubmed: 26718008
Hogan, B., Beddington, R., Constantini, F. & Lacy, E. Manipulating the Mouse Embryo: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 1994).
Cerceo, E., Rachoin, J. S., Gaughan, J. & Weisberg, L. Association of gender, age, and race on renal outcomes and mortality in patients with severe sepsis and septic shock. J. Crit. Care 61, 52–56 (2021).
pubmed: 33080528 doi: 10.1016/j.jcrc.2020.10.007
Wehrenpfennig, P., Drechsler, S., Weixelbaumer, K. M., Bahrami, S. & Osuchowski, M. F. Mouse model of posttraumatic abdominal sepsis: survival advantage of females over males does not depend on the cecum size. Eur. Surg. Res. 52, 83–89 (2014).
pubmed: 24820120 doi: 10.1159/000362543
Garcia, L. F., Singh, V., Mireles, B., Dwivedi, A. K. & Walker, W. E. Common variables that influence sepsis mortality in mice. J. Inflamm. Res. 16, 1121–1134 (2023).
pubmed: 36941984 pmcid: 10024505 doi: 10.2147/JIR.S400115
Shackelford, C., Long, G., Wolf, J., Okerberg, C. & Herbert, R. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol. Pathol. 30, 93–96 (2002).
pubmed: 11890482 doi: 10.1080/01926230252824761
Moreno, S. E. et al. IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J. Immunol. 177, 3218–3224 (2006).
pubmed: 16920961 doi: 10.4049/jimmunol.177.5.3218

Auteurs

Liliana Oliveira (L)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
IBMC - Instituto de Biologia Molecular e Celular, Porto, Portugal.

M Carolina Silva (MC)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
IBMC - Instituto de Biologia Molecular e Celular, Porto, Portugal.
Universidade de Aveiro, Aveiro, Portugal.

Ana P Gomes (AP)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
IBMC - Instituto de Biologia Molecular e Celular, Porto, Portugal.

Rita F Santos (RF)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
IBMC - Instituto de Biologia Molecular e Celular, Porto, Portugal.
ESS, Politécnico do Porto, Porto, Portugal.

Marcos S Cardoso (MS)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
IBMC - Instituto de Biologia Molecular e Celular, Porto, Portugal.
ESS, Politécnico do Porto, Porto, Portugal.

Ana Nóvoa (A)

Instituto Gulbenkian de Ciência, Oeiras, Portugal.

Hervé Luche (H)

Centre d'Immunophénomique (CIPHE), Aix Marseille Université, INSERM, CNRS, 13288, Marseille, France.

Bruno Cavadas (B)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.

Irina Amorim (I)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal.

Fátima Gärtner (F)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal.

Bernard Malissen (B)

Centre d'Immunophénomique (CIPHE), Aix Marseille Université, INSERM, CNRS, 13288, Marseille, France.

Moisés Mallo (M)

Instituto Gulbenkian de Ciência, Oeiras, Portugal.

Alexandre M Carmo (AM)

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. acarmo@ibmc.up.pt.
IBMC - Instituto de Biologia Molecular e Celular, Porto, Portugal. acarmo@ibmc.up.pt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH